Pharma-Bio Serv (OTCMKTS:PBSV – Get Free Report) is projected to post its resultson Wednesday, September 16th. Analysts expect Pharma-Bio Serv to post earnings of $0.03 per share and revenue of $2.70 million for the quarter.
Pharma-Bio Serv (OTCMKTS:PBSV – Get Free Report) last announced its quarterly earnings data on Monday, June 15th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Pharma-Bio Serv had a return on equity of 0.56% and a net margin of 0.68%.The firm had revenue of $2.70 billion during the quarter, compared to the consensus estimate of $2.70 million. On average, analysts expect Pharma-Bio Serv to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Pharma-Bio Serv Price Performance
Shares of OTCMKTS:PBSV opened at $0.54 on Monday. Pharma-Bio Serv has a 1-year low of $0.41 and a 1-year high of $1.36. The business’s 50 day moving average is $0.52 and its 200-day moving average is $0.52.
About Pharma-Bio Serv
Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc was founded in 1993 and is headquartered in Dorado, Puerto Rico.
Further Reading
- Five stocks we like better than Pharma-Bio Serv
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Pharma-Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma-Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.
